NEWS
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
PainReform (Nasdaq: PRFX) announced partial topline data from its Phase 3 clinical trial of PRF-110 for post-surgical pain management in bunionectomy patients.
PainReform (Nasdaq: PRFX) announced partial topline data from its Phase 3 clinical trial of PRF-110 for post-surgical pain management in bunionectomy patients.
The initial analysis shows statistically significant superiority over placebo in pain reduction during the first 48 hours post-surgery.
However, data for the subsequent 24-hour period, important for the primary endpoint assessment, remains unclear due to data incoherence.
The company is working with Lotus Clinical Research to resolve these data issues. PRF-110 is an oil-based, extended-release formulation of ropivacaine, designed to provide prolonged pain relief while reducing opioid dependency.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2536Followers
107Following
27KVisitors
Follow